深圳市精锋医疗科技股份有限公司（“精锋医疗-B”，02675）于2026年3月4日披露2026年2月股份变动月报表，报告期截至2026年2月28日。公告显示，公司注册股本（即“注册资本”）由上月底的323,602,948股H股及64,119,252股未上市股份合计387,722,200股，增至327,761,248股H股及64,119,252股未上市股份，合计391,880,500股。
根据公告，H股出现4,158,300股增发，系因超额配股权悉数行使所致，发行价为每股港币43.24。未上市股份则保持不变。报告期内，公司无购回或注销股份活动，亦无股份期权与股权激励计划的变动。公司确认其公众持股量已符合相关最低持股比例要求。
截至2026年2月28日，公司股本总数为391,880,500股。公告同时提及，公司经董事会正式授权批准所有发行事项，相关流程均遵守香港联交所《上市规则》及其它适用法规。该月报表由联席公司秘书吴梦媛签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.